Tourmaline Bio Statistics
Total Valuation
Tourmaline Bio has a market cap or net worth of $1.24 billion. The enterprise value is $998.75 million.
| Market Cap | 1.24B |
| Enterprise Value | 998.75M |
Important Dates
The next estimated earnings date is Thursday, November 13, 2025, before market open.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Tourmaline Bio has 25.80 million shares outstanding. The number of shares has increased by 53.98% in one year.
| Current Share Class | 25.80M |
| Shares Outstanding | 25.80M |
| Shares Change (YoY) | +53.98% |
| Shares Change (QoQ) | +0.25% |
| Owned by Insiders (%) | 8.48% |
| Owned by Institutions (%) | 58.79% |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.76 |
| P/TBV Ratio | 4.78 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 24.68, with a Debt / Equity ratio of 0.00.
| Current Ratio | 24.68 |
| Quick Ratio | 23.70 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -29.62% and return on invested capital (ROIC) is -21.42%.
| Return on Equity (ROE) | -29.62% |
| Return on Assets (ROA) | -20.85% |
| Return on Invested Capital (ROIC) | -21.42% |
| Return on Capital Employed (ROCE) | -39.53% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.20M |
| Employee Count | 74 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +80.44% in the last 52 weeks. The beta is 1.58, so Tourmaline Bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.58 |
| 52-Week Price Change | +80.44% |
| 50-Day Moving Average | 40.68 |
| 200-Day Moving Average | 22.74 |
| Relative Strength Index (RSI) | 89.34 |
| Average Volume (20 Days) | 653,270 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -102.45M |
| Pretax Income | -88.47M |
| Net Income | -88.47M |
| EBITDA | -102.41M |
| EBIT | -102.45M |
| Earnings Per Share (EPS) | -$3.44 |
Balance Sheet
The company has $239.23 million in cash and $145,000 in debt, giving a net cash position of $239.09 million or $9.27 per share.
| Cash & Cash Equivalents | 239.23M |
| Total Debt | 145,000 |
| Net Cash | 239.09M |
| Net Cash Per Share | $9.27 |
| Equity (Book Value) | 259.19M |
| Book Value Per Share | 10.09 |
| Working Capital | 239.01M |
Cash Flow
In the last 12 months, operating cash flow was -$86.28 million and capital expenditures -$25,000, giving a free cash flow of -$86.30 million.
| Operating Cash Flow | -86.28M |
| Capital Expenditures | -25,000 |
| Free Cash Flow | -86.30M |
| FCF Per Share | -$3.35 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Tourmaline Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -53.98% |
| Shareholder Yield | -53.98% |
| Earnings Yield | -7.15% |
| FCF Yield | -6.97% |
Analyst Forecast
The average price target for Tourmaline Bio is $49.05, which is 2.23% higher than the current price. The consensus rating is "Hold".
| Price Target | $49.05 |
| Price Target Difference | 2.23% |
| Analyst Consensus | Hold |
| Analyst Count | 12 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | 12.07% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |